A Korean nationwide surveillance on circulating rotavirus strains was conducted from September 2000 to August 2007 aiming to obtain prevaccine data for predicting vaccine effectiveness. The predominant strains among the 2779 strains analyzed varied annually and only approximately 50% had either a G or a P antigen present in both RotaTeq (Merck & Co. Inc., Whitehouse Station, NJ, USA) and Rotarix (GlaxoSmithKline, Brentford, UK).
© 2010 The Authors. Journal Compilation © 2010 European Society of Clinical Microbiology and Infectious Diseases.